The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD.

BACKGROUND The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends the use of forced expiratory volume in 1s (FEV(1)) to assess airways reversibility. The American Thoracic Society (ATS) and the European Respiratory Society (ERS) recommend FEV(1) and/or forced vital capacity (FVC). This study assessed whether FVC detects reversibility in more chronic obstructive pulmonary disease (COPD) patients than FEV(1) after acute short-acting bronchodilator inhalation. METHODS Plethysmographic data of 168 consecutive stable male COPD patients who underwent reversibility testing were analyzed. RESULTS Seventy-seven patients showed a clinically significant increase in FVC, whereas only 49 patients showed a clinically significant increase in FEV(1). Thus, FVC detected reversibility in 57% more patients than FEV(1). Of the 90 patients showing clinically significant reversibility, FEV(1) did not detect 41 patients that FVC detected, indicating a 45% difference. CONCLUSION FEV(1) underestimates acute bronchodilation effects. FVC should thus be a primary clinical outcome measure of bronchodilator reversibility in COPD, as it detects reversibility in more patients. This message, forgotten by GOLD, should be promoted in future consensus statements.

[1]  A. Gulsvik,et al.  Bronchodilator reversibility testing in an adult general population; the importance of smoking and anthropometrical variables on the response to a beta2-agonist. , 2006, Pulmonary pharmacology & therapeutics.

[2]  J. Hankinson,et al.  Interpretative strategies for lung function tests , 2005, European Respiratory Journal.

[3]  C. Persson.  Small airway relaxation--a forgotten medical need. , 2008, Pulmonary pharmacology & therapeutics.

[4]  S. Spencer,et al.  Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.

[5]  P. Calverley,et al.  Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease , 2001, Thorax.

[6]  J E Cotes,et al.  Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[7]  N. Anthonisen,et al.  Prognosis in chronic obstructive pulmonary disease. , 1990, The American review of respiratory disease.

[8]  S. Quadrelli,et al.  Evaluation of bronchodilator response in patients with airway obstruction. , 1999, Respiratory medicine.

[9]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[10]  A. Ramírez-Venegas,et al.  Salmeterol reduces dyspnea and improves lung function in patients with COPD. , 1997, Chest.

[11]  R. Zuwallack,et al.  Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. , 2003, Chest.

[12]  S. Kudoh,et al.  Correlation between bronchodilator responsiveness and quality of life in chronic obstructive pulmonary disease. , 2007, Allergology international : official journal of the Japanese Society of Allergology.

[13]  D. D. Briggs,et al.  The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. , 2000, Chest.

[14]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[15]  L. Pini,et al.  Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest , 2002, Thorax.

[16]  R. Berger,et al.  Acute postbronchodilator changes in pulmonary function parameters in patients with chronic airways obstruction. , 1988, Chest.

[17]  J. Stocks,et al.  Reference values for residual volume, functional residual capacity and total lung capacity. ATS Workshop on Lung Volume Measurements. Official Statement of The European Respiratory Society. , 1995, The European respiratory journal.

[18]  J. Ramsdell,et al.  Determination of bronchodilation in the clinical pulmonary function laboratory. Role of changes in static lung volumes. , 1979, Chest.

[19]  M. Rué,et al.  The bronchodilator test in chronic obstructive pulmonary disease: interpretation methods. , 2007, Respiratory medicine.

[20]  A. Gulsvik,et al.  Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community. , 2007, Respiratory medicine.

[21]  F Kummer,et al.  Evaluation of bronchodilator responses in patients with "irreversible" emphysema. , 2002, The European respiratory journal.

[22]  L. Forkert,et al.  Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. , 2002, Chest.

[23]  N. Meslier,et al.  Diagnostic value of reversibility of chronic airway obstruction to separate asthma from chronic bronchitis: a statistical approach. , 1989, The European respiratory journal.

[24]  The one best test for evaluating the effects of bronchodilator therapy. , 1977, Chest.

[25]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[26]  G. Viegi,et al.  Standardisation of the measurement of lung volumes , 2005, European Respiratory Journal.

[27]  A. Rossi,et al.  A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease. , 2005, Pulmonary pharmacology & therapeutics.

[28]  A Pedotti,et al.  Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD , 2005, Thorax.

[29]  R. Light,et al.  Should the FVC be considered in evaluating response to bronchodilator? , 1983, Chest.

[30]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[31]  A. Foresi,et al.  Effect of heliox breathing on dynamic hyperinflation in COPD patients. , 2004, Chest.

[32]  N. Anthonisen,et al.  Bronchodilator response in chronic obstructive pulmonary disease. , 1986, The American review of respiratory disease.

[33]  P. Chanez,et al.  Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. , 2007, Pulmonary pharmacology & therapeutics.

[34]  F. García-Río,et al.  Spirometric reference equations for European females and males aged 65–85 yrs , 2004, European Respiratory Journal.

[35]  M. Cazzola,et al.  Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease. , 1998, Respiratory medicine.

[36]  T. Schermer,et al.  Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. , 2007, Respiratory medicine.

[37]  Anthonisen Nr,et al.  Bronchodilator response in chronic obstructive pulmonary disease. , 1986 .

[38]  K. P. Van de Woestijne,et al.  Mechanisms for isolated volume response to a bronchodilator in patients with COPD. , 2000, Journal of applied physiology.

[39]  W. MacNee,et al.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper , 2004, European Respiratory Journal.

[40]  Standardized lung function testing. Official statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[41]  R. Pellegrino,et al.  Assessing the reversibility of airway obstruction. , 1998, Chest.

[42]  P. Chanez,et al.  Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial , 2007 .

[43]  A. Dirksen,et al.  Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[44]  T. Similowski,et al.  Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. , 1998, The European respiratory journal.

[45]  M Cazzola,et al.  Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD , 2003, European Respiratory Journal.

[46]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[47]  J. Hankinson,et al.  SERIES ''ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING'' Edited by V. Brusasco, R. Crapo and G. Viegi Number 5 in this Series Interpretative strategies for lung function tests , 2005 .

[48]  D. O’Donnell,et al.  Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[49]  D. O’Donnell.  Is sustained pharmacologic lung volume reduction now possible in COPD? , 2006, Chest.